Immuneering Corporation (IMRX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol IMRX
- Company Immuneering Corporation
- Price $2.31
- Changes Percentage 15.5
- Change 0.31
- Day Low $2.15
- Day High $2.51
- Year High $8.89
- Year Low $1
- Market Cap $68,499,354
- Price Avg 50 EMA (D) $1.75
- Price Avg 200 EMA (D) $2.88
- Exchange NASDAQ
- Volume 25,621,400
- Average Volume 6,319,768
- Open $2.45
- Previous Close $2
- EPS -1.74
- PE -1.33
- Earnings Announcement 2024-11-07 12:00:00
- Shares Outstanding $29,653,400
Company brief: IMMUNEERING CORPORATION (IMRX )
- Healthcare
- Biotechnology
- Dr. Benjamin J. Zeskind M.B.A., Ph.D.
- https://immuneering.com
- US
- N/A
- 07-30-2021
- US45254E1073
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.